Emcure Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE168P01015
NSEID: EMCURE
BSEID: 544210
View on NSE | View on BSE

INR

1,641.60

-21.3 (-1.28%)

BSENSE

May 08

BSE+NSE Vol: 3.25 lacs

{
  "main_header": {
    "sid": 10039308,
    "name": "Emcure Pharma",
    "stock_name": "Emcure Pharma",
    "full_name": "Emcure Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/emcure-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,641.60",
    "chg": -21.3,
    "chgp": "-1.28%",
    "dir": -1,
    "prev_price": "1,662.90",
    "mcapval": "31,098.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 544210,
    "symbol": "EMCURE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE168P01015",
    "curr_date": "May 08",
    "curr_time": "",
    "bse_nse_vol": "3.25 lacs",
    "exc_status": "Active",
    "traded_date": "May 08, 2026",
    "traded_date_str": "2026 05 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/emcure-pharma-10039308-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Emcure Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-3982715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_mojoScore_3982715.png",
        "date": "2026-05-09 10:10:36",
        "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects."
      },
      {
        "title": "Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-drops-804-5-key-factors-behind-this-weeks-decline-3982653",
        "imagepath": "",
        "date": "2026-05-09 10:01:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> New 52-week and all-time high at Rs.1,805 (intraday)</p>\n                    <p><strong>5 May:</strong> Stock hits another 52-week high at Rs.1,830.35</p>\n                    <p><strong>5 May:</strong> Q4 FY26 results reveal strong topline but margin pressures</p>\n                    <p><strong>6 May:</strong> Flat quarterly performance reported amid rising interest costs</p>\n                    <p><strong>8 May:</strong> Week closes at Rs.1,641.60, down 8.04%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,785.15</div></div>\n          ..."
      },
      {
        "title": "Are Emcure Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharmaceuticals-ltd-latest-results-good-or-bad-3978414",
        "imagepath": "",
        "date": "2026-05-06 19:19:53",
        "description": "Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape.\n\nOn the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful..."
      },
      {
        "title": "Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-reports-flat-quarterly-performance-amid-margin-pressures-3976687",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_fintrenddot_3976687.png",
        "date": "2026-05-06 08:00:15",
        "description": "Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold."
      },
      {
        "title": "Emcure Pharmaceuticals Q4 FY26: Strong Topline Growth Masks Margin Pressures and Elevated Valuations",
        "link": "https://www.marketsmojo.com/news/result-analysis/emcure-pharmaceuticals-q4-fy26-strong-topline-growth-masks-margin-pressures-and-elevated-valuations-3976503",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_quaterlyResult_3976503.png",
        "date": "2026-05-05 21:01:53",
        "description": "Emcure Pharmaceuticals Ltd. delivered a mixed performance in Q4 FY26, posting a consolidated net profit of ₹243.40 crores, representing a sequential increase of 5.58% quarter-on-quarter and a robust 28.81% year-on-year growth. However, the stock faced significant selling pressure, plunging 5.25% to ₹1,691.45 in the trading session following the results announcement, as investors grappled with margin compression concerns and premium valuations despite the company's strong revenue momentum."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1830.35",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-new-52-week-high-at-rs183035-3975497",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_priceRelatedfactors_3975497.png",
        "date": "2026-05-05 09:49:32",
        "description": "Surging past its previous peaks, Emcure Pharmaceuticals Ltd touched a new 52-week high of Rs 1830.35 on 5 May 2026, marking a remarkable 77.88% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price action, even as the broader market struggles to maintain its footing."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1825.5 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-all-time-high-at-rs18255-on-5-may-2026-3975432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_priceRelatedfactors_3975432.png",
        "date": "2026-05-05 09:34:57",
        "description": ""
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Signal Heightened Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-signal-heightened-price-attractiveness-3974702",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_3974702.png",
        "date": "2026-05-05 08:01:42",
        "description": "Emcure Pharmaceuticals Ltd has witnessed a significant re-rating in its valuation metrics, transitioning from an expensive to a very expensive stock within the Pharmaceuticals & Biotechnology sector. This shift accompanies a robust price rally, with the stock surging over 6% in a single trading session and outperforming benchmark indices substantially over multiple time horizons."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Surges 7.19% to Day's High of Rs 1805 — Outperforms Sector by 6.4 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-intraday-high-with-719-surge-on-4-may-2026-3974182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_priceRelatedfactors_3974182.png",
        "date": "2026-05-04 14:46:11",
        "description": "The Sensex edged up 0.39% on 4 May 2026, but Emcure Pharmaceuticals Ltd outpaced the broader market with a robust 7.19% gain, touching an intraday high of Rs 1805. This 6.4-percentage-point outperformance over its Pharmaceuticals &amp; Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift."
      }
    ],
    "total": 410,
    "sid": "10039308",
    "stock_news_url": "https://www.marketsmojo.com/news/emcure-pharmaceuticals-10039308"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-May-2026",
      "details": "Newspaper Publication of Audited Financial Results of the Company for the quarter and year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Corporate Action-Board approves Dividend",
      "datetime": "05-May-2026",
      "details": "Recommendation of Final Dividend for the Financial Year 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "05-May-2026",
      "details": "Investor presentation for financial year ending March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Emcure Pharmaceuticals Ltd is Rated Hold

2026-05-09 10:10:36

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects.

Read full news article

Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline

2026-05-09 10:01:59

Key Events This Week

4 May: New 52-week and all-time high at Rs.1,805 (intraday)

5 May: Stock hits another 52-week high at Rs.1,830.35

5 May: Q4 FY26 results reveal strong topline but margin pressures

6 May: Flat quarterly performance reported amid rising interest costs

8 May: Week closes at Rs.1,641.60, down 8.04%

Week Open

Rs.1,785.15

...

Read full news article

Are Emcure Pharmaceuticals Ltd latest results good or bad?

2026-05-06 19:19:53

Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape. On the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful...

Read full news article

Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures

2026-05-06 08:00:15

Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold.

Read full news article

Emcure Pharmaceuticals Q4 FY26: Strong Topline Growth Masks Margin Pressures and Elevated Valuations

2026-05-05 21:01:53

Emcure Pharmaceuticals Ltd. delivered a mixed performance in Q4 FY26, posting a consolidated net profit of ₹243.40 crores, representing a sequential increase of 5.58% quarter-on-quarter and a robust 28.81% year-on-year growth. However, the stock faced significant selling pressure, plunging 5.25% to ₹1,691.45 in the trading session following the results announcement, as investors grappled with margin compression concerns and premium valuations despite the company's strong revenue momentum.

Read full news article

Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1830.35

2026-05-05 09:49:32

Surging past its previous peaks, Emcure Pharmaceuticals Ltd touched a new 52-week high of Rs 1830.35 on 5 May 2026, marking a remarkable 77.88% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price action, even as the broader market struggles to maintain its footing.

Read full news article

Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1825.5 as Momentum Builds Across Timeframes

2026-05-05 09:34:57

Read full news article

Emcure Pharmaceuticals Ltd Valuation Shifts Signal Heightened Price Attractiveness

2026-05-05 08:01:42

Emcure Pharmaceuticals Ltd has witnessed a significant re-rating in its valuation metrics, transitioning from an expensive to a very expensive stock within the Pharmaceuticals & Biotechnology sector. This shift accompanies a robust price rally, with the stock surging over 6% in a single trading session and outperforming benchmark indices substantially over multiple time horizons.

Read full news article

Emcure Pharmaceuticals Ltd Surges 7.19% to Day's High of Rs 1805 — Outperforms Sector by 6.4 Percentage Points

2026-05-04 14:46:11

The Sensex edged up 0.39% on 4 May 2026, but Emcure Pharmaceuticals Ltd outpaced the broader market with a robust 7.19% gain, touching an intraday high of Rs 1805. This 6.4-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.